全文获取类型
收费全文 | 820篇 |
免费 | 45篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 32篇 |
妇产科学 | 26篇 |
基础医学 | 86篇 |
口腔科学 | 13篇 |
临床医学 | 77篇 |
内科学 | 176篇 |
皮肤病学 | 12篇 |
神经病学 | 25篇 |
特种医学 | 161篇 |
外科学 | 89篇 |
综合类 | 35篇 |
预防医学 | 20篇 |
眼科学 | 9篇 |
药学 | 66篇 |
中国医学 | 6篇 |
肿瘤学 | 39篇 |
出版年
2023年 | 9篇 |
2022年 | 4篇 |
2021年 | 13篇 |
2020年 | 6篇 |
2019年 | 13篇 |
2018年 | 10篇 |
2017年 | 4篇 |
2016年 | 29篇 |
2015年 | 55篇 |
2014年 | 25篇 |
2013年 | 30篇 |
2012年 | 30篇 |
2011年 | 27篇 |
2010年 | 37篇 |
2009年 | 34篇 |
2008年 | 36篇 |
2007年 | 15篇 |
2006年 | 17篇 |
2005年 | 20篇 |
2004年 | 12篇 |
2003年 | 15篇 |
2002年 | 13篇 |
2001年 | 16篇 |
2000年 | 13篇 |
1999年 | 12篇 |
1998年 | 23篇 |
1997年 | 42篇 |
1996年 | 33篇 |
1995年 | 27篇 |
1994年 | 24篇 |
1993年 | 23篇 |
1992年 | 11篇 |
1991年 | 11篇 |
1990年 | 17篇 |
1989年 | 28篇 |
1988年 | 18篇 |
1987年 | 15篇 |
1986年 | 16篇 |
1985年 | 8篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1974年 | 2篇 |
1970年 | 3篇 |
1968年 | 3篇 |
排序方式: 共有875条查询结果,搜索用时 0 毫秒
21.
Robert S. Makar Anand Padmanabhan Haewon C. Kim Christina Anderson Michele W. Sugrue Michael Linenberger 《Transfusion medicine reviews》2014,28(4):198-204
Limited literature describes the value of laboratory “triggers” to guide collection of peripheral blood (PB) hematopoietic progenitor cells (HPCs) by apheresis [HPC(A)]. We used a web-based survey to determine which parameters are used to initiate autologous HPC(A) collection in adult and pediatric patients and to identify common practice patterns. Members of the AABB Cellular Therapy Product Collection and Clinical Practices Subsection and the American Society for Apheresis HPC Donor Subcommittee drafted and developed relevant survey questions. A web link to the survey was distributed by electronic newsletter or email. Responses from 67 programs that perform autologous HPC(A) collections, including academic medical centers (n = 46), blood centers (n = 10), community hospitals (n = 5), and a variety of other medical institutions (n = 6), were analyzed. Ninety-three percent (62/67) of programs used a laboratory parameter to initiate HPC(A) collection. In both adult (40/54, 74%) and pediatric (29/38, 76%) patients, the PB CD34 + cell count was the most common parameter used to initiate HPC(A) collection. The median PB CD34 + trigger value was 10/μL for both patient populations. Among centers routinely using the PB CD34 + cell count to initiate apheresis, 51% (22/43) first sent the test before the patient presented for collection. Although more than 90% of centers used a laboratory test to trigger apheresis in cytokine-mobilized (44/48) or chemomobilized patients (50/53), only 57% (30/53) used a laboratory trigger if the patient was mobilized with granulocyte colony-stimulating factor plus plerixafor. Forty-two percent (21/50) of programs that routinely measured the PB CD34 + count before collection and discontinued further HPC(A) collection based on product CD34 + cell yield also stopped if the PB CD34 + value before apheresis was considered too low to proceed. Most programs use the PB CD34 + cell count to trigger autologous HPC(A) collection. Some centers also use this parameter to stop further collections. Laboratory tests are used less frequently to initiate apheresis when patients are mobilized with plerixafor. These data reveal ongoing diversity in clinical practices and suggest that consensus guidelines on use of laboratory parameters may further optimize HPC(A) collection. 相似文献
22.
23.
再发骨质疏松性椎体压缩骨折保守治疗患者出院后生存质量 总被引:1,自引:0,他引:1
目的:对比初次和再发骨质疏松性椎体压缩骨折(osteoporotic vertebral compression fractures,OVCFs)患者保
守治疗的生存质量,了解再次骨折对此类患者生存质量各方面的影响。方法:回顾性观察治疗OVCFs后出现再骨折
的患者30名(再骨折组)和同时期行保守治疗OVCFs后未发生再骨折的基本条件相似的患者30例(对照组),比较两组出
院后3个月时SF-36简明健康健康状况调查表的调查结果。结果:再骨折组治疗后的8个维度均不同程度较对照组变差
(均P<0.01)。结论:再骨折组患者的生存质量明显低于对照组,并且会进一步影响患者的心理预期、情绪和社会活动
的各个方面。 相似文献
24.
KA Hodgkinson SP Connors N Merner A Haywood T‐L Young WJ McKenna B Gallagher F Curtis AS Bassett PS Parfrey 《Clinical genetics》2013,83(4):321-331
To determine the phenotype and natural history of a founder genetic subtype of autosomal dominant arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by a p.S358L mutation in TMEM43. The age of onset of cardiac symptoms, clinical events and test abnormalities were studied in 412 subjects (258 affected and 154 unaffected), all of which occurred in affected males significantly earlier and more often than unaffected males. Affected males were hospitalized four times more often than affected females (p ≤ 0.0001) and died younger (p ≤ 0.001). The temporal sequence from symptoms onset to death was prolonged in affected females by 1–2 decades. The most prevalent electrocardiogram (ECG) manifestation was poor R wave progression (PRWP), with affected males twice as likely to develop PRWP as affected females (p ≤ 0.05). Left ventricular enlargement (LVE) occurred in 43% of affected subjects, with 11% fulfilling criteria for dilated cardiomyopathy. Ventricular ectopy on Holter monitor was common and occurred early: the most diagnostically useful clinical test. No symptom or test could rule out diagnosis. This ARVC subtype is a sex‐influenced lethal arrhythmogenic cardiomyopathy, with a unique ECG finding, LV dilatation, heart failure and early death, where molecular pre‐symptomatic diagnosis has the greatest clinical utility. 相似文献
25.
26.
27.
28.
29.
30.